10-Q: Indivior Reports Q2 Profit Amid Strong SUBLOCADE Growth and Strategic Nasdaq Shift

Indivior PLC reported a significant turnaround to net income in the second quarter of 2025, driven by robust SUBLOCADE sales and improved gross margins, despite ongoing litigation challenges and a one-time UK tax settlement.

Summary

• Net revenue for the three months ended June 30, 2025, increased by 1% to $302 million, compared to $299 million in the same period of 2024.
• For the six months ended June 30, 2025, net revenue decreased by 3% to $568 million, down from $583 million in 2024.
• SUBLOCADE net revenue (U.S. and Rest of World) grew by 9% to $209 million in Q2 2025 and 4% to $385 million for the six months, reflecting volume increases and favorable rebate accrual changes.
• U.S. net revenue from Sublingual & other products declined by 18% to $52 million in Q2 2025 and 15% to $107 million for the six months, due to increased competitive activity and lower pricing.
• PERSERIS net revenue decreased by 37% to $8 million in Q2 2025 and 49% to $12 million for the six months, following the discontinuation of commercial sales support in July 2024.
• Gross profit for Q2 2025 was $250 million, up from $220 million in Q2 2024, with gross margin improving to 83% from 74%.
• Operating income for Q2 2025 was $72 million, a significant improvement from an operating loss of $118 million in Q2 2024.
• Net income for Q2 2025 was $18 million, compared to a net loss of $97 million in Q2 2024.
• For the six months ended June 30, 2025, net income was $65 million, a substantial improvement from a net loss of $36 million in 2024.
• Cash and cash equivalents increased to $510 million as of June 30, 2025, from $319 million at December 31, 2024, partly due to timing of government rebate invoice processing.
• Accrued rebates and product returns increased to $709 million as of June 30, 2025, from $562 million at December 31, 2024.
• A $33 million tax reserve was recorded in Q2 2025 related to a probable settlement with U.K. HMRC concerning prior years' intercompany financing arrangements.
• The company completed cancellation of its London Stock Exchange listing in July 2025 and now trades exclusively on Nasdaq.
• Effective June 30, 2025, the company became a member of the U.S. small-cap Russell 2000 Index and the broad-market Russell 3000 Index.
• The company no longer qualifies as a foreign private issuer under U.S. securities laws as of June 30, 2025, and will become subject to U.S. domestic issuer rules beginning January 1, 2026.

Sentiment

Score: 7

Explanation: The company shows strong financial improvement in profitability and cash flow, driven by its key product SUBLOCADE. Strategic moves like the Nasdaq listing are positive. However, significant unquantified litigation risks related to opioid and dental claims remain a notable concern, preventing a higher score.

Positives

• SUBLOCADE, the company's key product, demonstrated strong growth with a 9% increase in net revenue for Q2 2025 and 4% for the six months ended June 30, 2025.
• Operating income significantly improved to $72 million in Q2 2025 from a $118 million loss in Q2 2024, and to $138 million for the six months from a $43 million loss in 2024.
• Net income turned positive to $18 million in Q2 2025 from a $97 million loss in Q2 2024, and to $65 million for the six months from a $36 million loss in 2024.
• Gross margin increased to 83% in Q2 2025 from 74% in Q2 2024, and to 83% from 80% for the six months, partly due to lower costs related to the discontinuation of PERSERIS marketing.
• Net cash provided by operating activities increased substantially to $233 million for the six months ended June 30, 2025, from $51 million in the prior year, benefiting from the timing of rebate payments.
• The company successfully resolved its last remaining legacy antitrust litigation with a final $20 million accrual payment.
• The Opiant shareholder class action complaint was dismissed by the court on June 6, 2025, and the plaintiff's appeal time has expired, resolving this litigation.
• The UK Supreme Court refused permission to appeal the strike-out of the representative action in the UK Shareholder Claims, reducing a significant legal overhang.
• The strategic decision to delist from the London Stock Exchange and trade exclusively on Nasdaq aligns with the company's focus on U.S. SUBLOCADE growth and enhances its capital markets footprint.
• Inclusion in the Russell 2000 and Russell 3000 Indexes is expected to increase visibility and liquidity for the company's shares.

Negatives

• Overall net revenue for the six months ended June 30, 2025, decreased by 3% compared to the prior year.
• Net revenue from Sublingual & other products continued to decline, falling 18% in Q2 2025 and 15% for the six months, due to increased competitive activity and lower pricing.
• PERSERIS net revenue significantly decreased by 37% in Q2 2025 and 49% for the six months, following the discontinuation of marketing and promotion activities.
• A substantial litigation settlement expense of $160 million was recorded in Q2 2025 and for the six months, compared to $1 million in the prior year periods.
• The effective income tax rate was high at 71% for Q2 2025 and 46% for the six months, primarily due to a $33 million tax reserve for a UK HMRC settlement and a UK global minimum top-up tax.
• The company maintains a negative working capital position, with current liabilities exceeding current assets by $106 million as of June 30, 2025.
• Total liabilities exceed total assets by $257 million as of June 30, 2025.
• Accrued rebates and product returns increased significantly by $147 million from December 31, 2024, to June 30, 2025, primarily due to the timing of government rebate invoice processing.

Risks

• Ongoing civil opioid litigation, including cases in the Opioid MDL and individual personal injury claims, with no estimate of total possible loss at this time.
• Unresolved private plaintiff cases related to opioid litigation, including neonatal abstinence syndrome (NAS) claims and the WV MLP Action, for which no estimate of possible loss can be made.
• Numerous lawsuits alleging SUBOXONE Film caused dental injury, with 1,877 cases (21,402 plaintiffs) in the Dental MDL and additional state court and class action complaints, for which no estimate of possible loss can be made.
• Pending multiparty actions in the U.K. Shareholder Claims, despite the successful strike-out of the representative action, with no estimate of possible loss.
• U.S. Shareholder Claims class action lawsuit was dismissed, but plaintiffs have 30 days to amend their complaint, indicating potential for continued litigation.
• Uncertainty regarding the implications of the 'One Big Beautiful Bill Act' and other regulatory changes on U.S. tax laws and Medicaid funding/eligibility rules, which could impact the business.
• Potential for U.S. federal government tariffs and retaliatory tariffs from other countries to impact revenues and margins, particularly given 85% of revenues are from the U.S. and key products are manufactured there.
• The company's negative working capital position, while currently manageable, requires sustained sales volume performance and no material change in the timing of collections and rebate payments to maintain liquidity.

Future Outlook

The company expects gross margin to remain in the low-to-mid 80 percent range for the remainder of 2025. Research and development expenses are anticipated to continue tracking below 2024 levels throughout 2025, as the company refocuses its development pipeline on Phase 2 OUD assets (INDV-2000 and INDV-6001). Incremental growth from new products in the Rest of the World is expected to at least offset the decline in the legacy tablet business in 2025. The opt-in process for opioid litigation settlements is expected to be complete in or before November 2025. The company anticipates capital expenditures of $50 million to $70 million for the full year 2025, primarily for the Raleigh Manufacturing Facility, after which they are expected to revert to historical levels. The company believes its existing cash, investments, and cash from operations will meet anticipated cash needs for at least the next twelve months, contingent on sustained sales volume and consistent timing of collections and rebate payments.

Management Comments

• The company's vision is that all patients will have access to evidence-based treatment for OUD, and it is dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease.
• The London Stock Exchange listing cancellation and exclusive Nasdaq trading aligns to the company's capital markets footprint and a stronger focus on SUBLOCADE growth in the U.S.
• The increase in gross margin primarily reflects costs of $41 million in the 2024 periods related to the discontinuation of marketing and promotion of PERSERIS.
• Higher selling, general and administrative expenses in Q2 2025 reflect a $14 million increase in marketing, primarily for U.S. SUBLOCADE, partly offset by lower general and administrative expenses driven by streamlining actions taken in 2024.
• The decrease in research and development expenses primarily reflects the company's actions to refocus its development pipeline on the Phase 2 OUD assets (INDV-2000 and INDV-6001).
• The HMRC settlement relates to aspects of prior years' intercompany financing arrangements and is not expected to impact future tax rates.
• The company believes its existing cash and cash equivalents and investments together with cash generated from operations and debt will enable its anticipated cash needs to be met for at least the twelve-month period following the issuance of this Form 10-Q.

Industry Context

Indivior operates in the pharmaceutical sector, specifically focusing on opioid use disorder (OUD) treatments. The company's strong performance in SUBLOCADE, a long-acting injectable, aligns with a broader industry trend towards more convenient and effective long-term treatment options for chronic conditions. The decline in its sublingual products reflects increasing generic competition, a common challenge for pharmaceutical companies with off-patent drugs. The strategic shift to a Nasdaq-only listing and inclusion in Russell indexes indicates a move towards aligning with U.S. capital markets, potentially seeking greater investor visibility and liquidity within the largest market for its key product, SUBLOCADE. The ongoing legal challenges, particularly related to opioids and product design, highlight the significant regulatory and litigation risks inherent in the pharmaceutical industry, especially for companies involved in pain management and addiction treatments.

Comparison to Industry Standards

• The company's gross margin of 83% for the six months ended June 30, 2025, is strong and generally competitive within the specialty pharmaceutical sector, particularly for companies with patented, high-value products like SUBLOCADE. This compares favorably to some generic-focused pharmaceutical companies which often have gross margins in the 40-60% range.
• The significant increase in cash from operating activities to $233 million for the six months ended June 30, 2025, demonstrates strong operational cash generation, which is a positive indicator compared to industry peers, especially those facing substantial litigation costs.
• The company's focus on OUD treatments positions it in a growing market segment, as the opioid crisis continues to drive demand for effective therapies. While direct comparable companies are not explicitly named in the filing, the growth of SUBLOCADE suggests it is gaining market share against other buprenorphine-based treatments, such as generic sublingual products.
• The discontinuation of PERSERIS marketing and refocusing of R&D on Phase 2 OUD assets (INDV-2000 and INDV-6001) indicates a strategic streamlining, which can be a positive move for a company of its size to optimize resource allocation, similar to how larger pharmaceutical companies divest non-core assets or narrow their pipeline focus.

Management Changes

Corporate Governance

Legal Proceedings

• A $52 million scheduled payment was made during the six months ended June 30, 2025, related to the DOJ settlement.
• An installment of $5 million was paid in the six months ended June 30, 2025, in relation to the last remaining antitrust litigation, with a remaining accrual of $20 million.
• The company has an accrual of $79 million for a settlement covering certain opioid litigation, including cases in the Opioid MDL, with an opt-in process expected to be complete by November 2025; Maryland is the only state not opting in.
• Private plaintiff cases against the company related to opioid litigation, including neonatal abstinence syndrome (NAS) claims and the WV MLP Action, remain unresolved, with no estimate of total possible loss.
• Numerous lawsuits allege SUBOXONE Film caused dental injury, with 1,877 cases (21,402 plaintiffs) consolidated in the Dental MDL, and additional state court and class action complaints in Canada; no estimate of possible loss can be made.
• The UK Supreme Court refused permission to appeal the strike-out of the representative action in the U.K. Shareholder Claims, but multiparty actions remain pending.
• A U.S. Shareholder Claims class action lawsuit was dismissed by the court on April 22, 2025, but plaintiffs have 30 days to amend their complaint.
• A class action complaint related to Opiant Shareholder Claims was dismissed by the Delaware Court of Chancery on June 6, 2025, and the plaintiff's time to appeal has expired, resolving this matter.

Stakeholder Impact

• Shareholders: Experienced a significant improvement in net income and EPS, but face ongoing uncertainty from substantial unquantified litigation risks. The Nasdaq-only listing and Russell index inclusion may improve share visibility and liquidity. Non-executive directors' share purchase plan aligns their interests with shareholders.
• Employees: The company is refocusing its development pipeline and streamlining operations, which may impact certain roles, but also aims to strengthen the executive team and focus on core OUD treatments.
• Customers (patients and healthcare providers): Continued focus on SUBLOCADE aims to provide access to evidence-based treatment for OUD. Discontinuation of PERSERIS marketing may affect access to that specific product.
• Suppliers: The termination of the Master Development and Supply Agreement with Curia Massachusetts, Inc. indicates a consolidation of manufacturing locations, which will impact Curia Massachusetts but not Curia New Mexico.
• Creditors: The company's liquidity position is deemed sufficient to meet obligations for at least the next 12 months, despite negative working capital, which should reassure creditors.

Next Steps

• Monitor the completion of the opt-in process for opioid litigation settlements, expected in or before November 2025.
• Observe the progress of the INDV-2000 Phase 2 proof of concept study, with the estimated last subject last visit expected in late 2025.
• Evaluate the impact of the 'One Big Beautiful Bill Act' and other U.S. tax law changes, effective from 2025 to 2027.
• Track the transition to U.S. domestic issuer rules, effective January 1, 2026, and its implications for corporate governance and reporting.
• Monitor the termination of the Master Development and Supply Agreement with Curia Massachusetts, Inc., effective January 31, 2026, and its impact on manufacturing consolidation.
• Assess the impact of the Non-Executive Director Purchase Plan on share price and insider ownership, with purchases commencing October 1, 2025.

Key Dates

Recommendation

The company's core product, SUBLOCADE, is performing strongly, driving significant improvements in profitability and cash flow. Strategic moves like the Nasdaq-only listing and Russell index inclusion are positive for market visibility. However, the company faces substantial and unquantified legal liabilities from ongoing opioid and dental litigation, which represent a significant overhang. While some legal matters have been resolved, the remaining risks are material. The negative working capital position, though managed, adds a layer of financial complexity. A 'hold' recommendation is appropriate for a seasoned investor, as the positive operational momentum is balanced by the considerable, uncertain legal risks. Investors should monitor litigation developments closely.

Keywords

Opioid Use Disorder, SUBLOCADE, Pharmaceutical, SEC Filing, Quarterly Report, Financial Results, Litigation, Corporate Governance, Nasdaq Listing, Russell Index, Drug Manufacturer, OUD Treatment, Buprenorphine, Nalmefene, Risk Factors, Shareholder Claims, Tax Settlement